28 Strategy Execution and Evolves its Executive Committee
PARIS--(BUSINESS WIRE)-- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers' excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness.
Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability.
The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs.
Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization.
All other Business and Support Functions will remain under their current leaders.
Hinda Gharbi, Chief Executive Officer of Bureau Veritas comments: 'By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy.
This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.'
***
The transition period will extend from July 1 st to the end of August 2025.
Effective September 1 st 2025, the Group Executive Committee will be structured and composed as follows:
Regions:
Europe: Executive Vice-President > Vincent Bourdil
Middle East Caspian & Africa: Executive Vice-President > Khurram Majeed
Asia Pacific: Executive Vice-President > Surachet Tanwongsval
Americas: Executive Vice-President to be appointed before year end
Product Lines:
Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny
Urbanization and Assurance: Executive Vice-President > Marc Roussel
Consumer Products Services: Executive Vice-President > Catherine Chen
Business Functions:
Corporate development & sustainability: Executive Vice-President > Juliano Cardoso
Chief Performance Officer: Executive Vice-President > Laurent Louail
Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires
Support Functions:
Chief Financial Officer: Executive Vice-President > François Chabas
Chief People Officer: Executive Vice-President > Maria Lorente Fraguas
Legal affairs & Internal Audit: Executive Vice-President > Beatrice Place-Faget
***
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.
***
Biographies:
Vincent Bourdil, appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe.
Khurram Majeed remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa.
Surachet Tanwongswal remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies.
Matthieu Gondallier de Tugny, appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore.
Marc Roussel, appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France.
Catherine Chen remains Executive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services.
Laurent Louail, appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance.
Juliano Cardoso remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability.
Philipp Karmires remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer.
François Chabas remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance.
Maria Lorente Fraguas remains Executive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer.
Béatrice Place-Faget remains Executive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
CVMSDC Invites Small Businesses to Pursue 'Accessible Connections' During Annual Business Opportunity Conference (BOC25), Aug. 3-5 in Charleston, SC
CHARLESTON, S.C., June 18, 2025--(BUSINESS WIRE)--The Carolinas-Virginia Minority Supplier Development Council will host its 48th annual Business Opportunity Conference (BOC25) on Aug. 3-5 at the Marriott Lockwood in Charleston, South Carolina. In addition to a welcome reception hosted at the International African American Museum, the two-day business program will highlight the theme of Accessible Connections, in alignment with intentional efforts by The Council to make access and inclusion integral parts of doing business. This year's conference will feature a scholarship swing golf tournament, along with a series of workshops for corporate partners, small business owners and certified Minority Business Enterprises (MBEs) – featuring keynote speakers, networking sessions, panel discussions, Open Roundtable "Business Connections" matchmaking between corporations and business owners, an artisans vendor market and an awards reception to recognize top small business performers and corporations. CVMSDC also will recognize young entrepreneurs from the student pitch competition as part of the conference and hold a free student workshop on entrepreneurship as a career path. Registration is open with $200 off for all small business owners to attend this impactful conference. The title sponsor for BOC25 is SONOCO. CVMSDC President & CEO Dominique Milton said: "True progress begins with access. At CVMSDC, we believe that making meaningful connections isn't just about networking—it's also about breaking down barriers, unlocking opportunities, and ensuring that our small business community has access to the resources they need to develop and grow their companies." Carolinas-Virginia Minority Supplier Development Council is a non-profit corporation chartered to enhance business opportunities for small business owners and certified MBEs by providing support through developing mutually beneficial networking opportunities with corporate partners and promoting business development through its four key pillars of advocacy, certification, connections and development. For more information or to register for BOC25, visit: View source version on Contacts Media Contact: PR PROS vk@ / (336) 362-9668
Business Wire
28 minutes ago
- Business Wire
Satellos Bioscience Shareholders Elect Two New Board Members
TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. 'I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,' said Frank Gleeson, Satellos co-founder and CEO. 'We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.' A highly accomplished biotech and pharmaceutical executive, Dr. Loew-Friedrich is recognized as the senior clinical leader who shaped UCB into a global powerhouse in neurology and immunology. Serving as executive vice president and chief medical officer until 2024, she led UCB's worldwide development and regulatory strategy for over two decades, overseeing the global approvals of multiple blockbuster therapies, including Cimzia, Briviact, Evenity, Rystiggo, Zilbrysq, and Bimzelx. Her leadership was instrumental in advancing both common and rare disease treatments, with a deep and sustained commitment to improving outcomes for underserved patient populations. Prior to UCB, Loew-Friedrich held senior R&D roles at Schwarz Pharma, BASF Pharma, and Hoechst/Aventis, where she contributed to the development and success of market-leading drugs such as Humira, Arava, Actonel, Vimpat, and Neupro. Dr. Ho is a seasoned pharmaceutical and biotech executive with broad leadership experience across commercial strategy, business development, financing, and board governance. He has held senior roles at global companies including Dermira (Eli Lilly), UCB, Allergan (AbbVie), Novartis, and AstraZeneca, with expertise spanning ophthalmology, immunology, oncology, and dermatology. As CEO of Medigene AG, he led a strategic transformation and established and extended key partnerships with BioNTech, Regeneron, WuXi Biologics and EpimAb Biotherapeutics. Previously, as EVP & chief business officer at Connect Biopharma, he was instrumental in raising over $350 million through IPO and private funding. He also serves on the boards of Antennova Inc. and Peptomyc S.L., and as executive-in-residence at New Rhein Healthcare Investors. As part of the Annual General Meeting, Rima Al-awar, Ph.D., William Jarosz, J.D., and William McVicar, Ph.D., did not stand for reelection. 'I want to personally thank Rima, Bill and Bill for their dedicated service, thoughtful leadership and support,' said Gleeson. 'Their guidance helped position Satellos for continued progress, and we wish them all the best in their future endeavors.' About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Notice on Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. 530509798v.1
Business Wire
28 minutes ago
- Business Wire
SouthBank Legal Expands Corporate Compliance, White Collar, and Investigations Team With Hire of Former Senior ADM and Caterpillar In-House Counsel Brendan J. Gardiner
SOUTH BEND, Ind.--(BUSINESS WIRE)--SouthBank Legal is pleased to announce that Brendan J. Gardiner has joined the firm as a Partner. Based in Boston, MA, Gardiner will focus his practice on helping companies and institutions manage their compliance and regulatory exposure, including enhancing their compliance programs, conducting due diligence, leading sensitive internal investigations, and designing and implementing effective remediation plans. Gardiner joins the firm's high-profile White Collar and Investigations practice team after almost 20 years as in-house counsel for Archer Daniels Midland (ADM) and Caterpillar Inc. His move highlights an industry trend of prominent in-house lawyers returning to private practice at premier law firms. 'We are excited to have Brendan join us and bring his vast in-house experience to assist CLOs and GCs assess and navigate risk for their companies,' stated Jesse Barrett, SouthBank Legal's Washington, DC managing partner and Chambers USA -ranked White-Collar and Investigations attorney. 'Increasingly, our clients are providing us the opportunity to help them proactively manage a full array of legal, compliance, and geopolitical risks, and Brendan's experience strengthens our ability to partner with clients to understand and address those risks before they materialize. I look forward to working alongside him in advising Fortune 500 and mid-market domestic and international clients in all aspects of their compliance operations.' Before joining SouthBank Legal, Gardiner was Vice President and Deputy General Counsel for ADM, where he oversaw a global team of over 100 attorneys and legal professionals throughout 19 countries, providing a full scope of legal practices and processes to support ADM's operations across 200+ countries. Prior to that, he was Chief Litigation and Regulatory Counsel for ADM. Before joining ADM, he was Lead Counsel, International Trade and Anti-Corruption for Caterpillar Inc., where he advised the company on anti-bribery, international sanctions, and tariff-related matters. Additionally, Gardiner was Lead Regional Counsel (EMEA), based in Brussels, and Lead Business Unit Counsel (Power Generation), based in California, for Caterpillar-owned Solar Turbines, Inc. Complementing his legal background, Gardiner has considerable experience designing and implementing insurance-based solutions to manage legal, operational, and geopolitical risks, having served as Director of Insurance and Risk Management at ADM. 'I am thrilled to be joining such an impressive team of lawyers at SouthBank Legal,' stated Gardiner. 'As the range and complexity of risks that CLOs and GCs are being asked to manage grows, in-house teams are increasingly looking to skilled outside lawyers who can provide high-quality, practical, business-oriented advice in a cost structure that meets their needs. SouthBank is a recognized leader in this space, and I look forward to working with the firm's impressive and growing list of clients across all industries. I have been in their shoes and can help them think about risk holistically and design solutions to address challenges before they arise. Having Jesse, who's a former federal prosecutor, and other incredible attorneys on the same team allows us to handle any range of scenarios, including when engagement with government regulators becomes necessary.' Gardiner clerked for the Honorable Susan H. Black at the U.S. Court of Appeals for the Eleventh Circuit. He received his J.D., magna cum laude, from Notre Dame Law School, where he was the Law Review Executive Editor, and his B.A. from the University of Notre Dame. Gardiner is the latest addition to SouthBank Legal's growing team. Most recently, the firm announced the addition of Maggie King and Gregory Guest. King, a recognized leader in the evolving legal and regulatory frameworks surrounding AI and data, focuses on technology, AI, and intellectual property aspects of business and corporate matters, including licensing and M&A projects. She also counsels clients on governance, risk management, and regulatory compliance related to generative AI, cryptocurrency, and sensitive data. An experienced data scientist, King practiced in a Tier 1 Technology Law group at a top ranked Am Law 100 firm and served as a clerk for Judge Thomas L. Kirsch II on the U.S. Court of Appeals for the Seventh Circuit. Guest has extensive experience with buyers and sellers in both financial and strategic acquisitions, and serves as advisor to entrepreneurs, investors, and closely held businesses. In addition, he advises on corporate workouts and restructuring. Guest clerked for the Honorable Lee M. Jackwig on the U.S. Bankruptcy Court for the Southern District of Iowa and practiced at an Am Law 200 firm in Michigan. SouthBank Legal, a Chambers USA ranked firm, routinely delivers smart, cost-effective business solutions to Fortune 500 global leaders as well as early-stage industry disrupters, guiding and fighting for clients in their highest-profile, highest-risk litigation from its offices in Washington, DC, Grand Rapids, MI, and northern Indiana. For more information, please visit
